Phase I/II Study of the Rituximab-EPOCT Regimen in Combination with Granulocyte Colony-Stimulating Factor in Patients with Relapsed or Refractory Follicular Lymphoma Including Evaluation of Its Cardiotoxicity Using B-Type Natriuretic Peptide and Troponin T Levels
Purpose: Standard treatment for relapsed or refractory follicular lymphoma has not been established. Doxorubicin is often given during the initial treatment. The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy. Experimental Design: The R-EPOCT (rituximab...
Saved in:
Published in | Clinical cancer research Vol. 11; no. 2; pp. 697 - 702 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.01.2005
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Purpose: Standard treatment for relapsed or refractory follicular lymphoma has not been established. Doxorubicin is often given during
the initial treatment. The dosage or drugs chosen for salvage therapy are limited by doxorubicin-induced cardiomyopathy.
Experimental Design: The R-EPOCT (rituximab with etoposide, vincristine, pirarubicine, cyclophosphamide, and prednisone) regimen, in which less
cardiotoxic pirarubicine is used instead of doxorubicin, with granulocyte colony-stimulating factor (G-CSF) was administered
to 20 patients with relapsed or refractory follicular lymphoma. The safety (especially cardiotoxicity) and efficacy of this
regimen were studied. As markers of cardiotoxicity, serum troponin T and plasma B-type natriuretic peptide (BNP) levels were
measured.
Results: Adverse reactions occurred in 14 of the 20 patients and mainly consisted of grade 3/4 hematologic toxicity. In the evaluation
of cardiotoxicity, the BNP level was slightly elevated before the treatment in two patients and the BNP level did not significantly
increase after R-EPOCT treatment. The troponin T level was undetectable before and after the treatment in all patients. The
response rate was 100%, with complete remission in 16 patients (80%). G-CSF administration increased both Fc γ receptor type
I expression on neutrophils and antibody-dependent cellular cytotoxicity activity. There were no significant differences in
the levels of Fc γ receptor type I expression nor antibody-dependent cellular cytotoxicity activity after three or five cycles
of the treatment.
Conclusion: We conclude that the combination of R-EPOCT and G-CSF is well tolerated. This regimen was not cardiotoxic. We are planning
a randomized trial to compare the efficacy between R-EPOCT and a combination of R-EPOCT with G-CSF. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.697.11.2 |